13
Feb

When hedge fund veteran Martin Shkreli debuted Retrophin, his biotech play, more than few market watchers reacted with healthy skepticism and even open mockery. But now the company’s plans to cash in with a rare-disease treatment have made it a hit with investors, with shares skyrocketing more than 40%.

…read more

Source: Rare disease deal sends Shkreli’s Retrophin soaring

    

0 No comments